Articles tagged ‘NICE’

The National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of Multaq® (dronedarone) for the treatment of atrial fibrillation (AF).

The National Institute for Health and Clinical Excellence (NICE) has issued its final appraisal determination on dronedarone (Multaq) recommending the drug as an option for non-permanent atrial fibrillation (AF) in selected patients. (1)

The National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD)1 for Multaq® (dronedarone) indicating its intention to recommend its use for the management of patients with atrial fibrillation (AF).

NICE is in the process of updating its clinical guideline on the management of chronic heart failure in adults and has now published its draft recommendations for public consultation. Since the original guideline was published in 2003, new high-quality evidence from randomised controlled trials in diagnosis, treatment and monitoring have been published. This partial update will ensure that the recommendations take into account the new evidence available.